A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma

TY - JOUR

T1 - A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma

AU - Ezughah, Francesca I.

AU - Dawe, Robert S.

AU - Ibbotson, Sally H.

AU - Fleming, Colin J.

PY - 2008

Y1 - 2008

N2 - Objectives: This study was designed to compare the safety and efficacy of two cycled dosing regimens of imiquimod 5% cream for treatment of superficial basal cell carcinoma (sBCC). Methods: Patients (n=32) were randomized to receive one of two treatment regimens: 8 weeks of treatment with once-daily dosing for alternate weeks (RI) and 5 weeks of once-daily dosing with a 1-week interval in the middle of the course (R2). Efficacy measures were tumour clearance at weeks 19 and 52 and measures of patients' acceptability. Results: Data from 30 patients (13 females), 14 on RI and 16 on R2, were analysed. The results revealed an initial clearance rate of 64% at week 19 for R1 and 81% for R2 (95% CI for difference: -14% to 45%, p=0.21). However, clearance rates at week 52 were significantly different: 43% for R1 and 88% for R2 (95% CI for difference: 11% to 68%, p=0.02). There was no difference in acceptability of treatment as measured by composite median visual analogue scores at week 8. Conclusion: Five weeks of 5% imiquimod cream once daily with a 1-week interval was more effective but as well tolerated as the 8-week alternate week regimen for sBCC.

AB - Objectives: This study was designed to compare the safety and efficacy of two cycled dosing regimens of imiquimod 5% cream for treatment of superficial basal cell carcinoma (sBCC). Methods: Patients (n=32) were randomized to receive one of two treatment regimens: 8 weeks of treatment with once-daily dosing for alternate weeks (RI) and 5 weeks of once-daily dosing with a 1-week interval in the middle of the course (R2). Efficacy measures were tumour clearance at weeks 19 and 52 and measures of patients' acceptability. Results: Data from 30 patients (13 females), 14 on RI and 16 on R2, were analysed. The results revealed an initial clearance rate of 64% at week 19 for R1 and 81% for R2 (95% CI for difference: -14% to 45%, p=0.21). However, clearance rates at week 52 were significantly different: 43% for R1 and 88% for R2 (95% CI for difference: 11% to 68%, p=0.02). There was no difference in acceptability of treatment as measured by composite median visual analogue scores at week 8. Conclusion: Five weeks of 5% imiquimod cream once daily with a 1-week interval was more effective but as well tolerated as the 8-week alternate week regimen for sBCC.

KW - basal cell cancer

KW - cycled dosing regimens

KW - imiquimod

KW - randomized parallel study

KW - superficial basal cell carcinoma

KW - CREAM

KW - EUROPE

U2 - 10.1080/09546630701557965

DO - 10.1080/09546630701557965

M3 - Article

C2 - 17917935

SN - 0954-6634

VL - 19

SP - 111

EP - 117

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

IS - 2

ER -